Tables | Number 28 | Special Reports | HIV Surveillance | Reports | Resource Library | HIV/AIDS

Table 1. Participants, by project area—Medical Monitoring Project, United States, 2019
Project area	No. sampled	No. participating	% participating^a	% of total
California (excluding Los Angeles County and San Francisco)	500	218	43.6	5.3
Chicago, IL	400	161	40.3	3.9
Delaware	400	189	47.3	4.6
Florida	800	315	39.4	7.7
Georgia	500	218	43.6	5.3
Houston, TX	400	181	45.3	4.4
Illinois (excluding Chicago)	200	67	33.5	1.6
Indiana	400	171	42.8	4.2
Los Angeles County, CA	400	167	41.8	4.1
Michigan	400	180	45.0	4.4
Mississippi	400	154	38.5	3.8
New Jersey	500	220	44.0	5.4
New York (excluding New York City)	200	82	41.0	2.0
New York City, NY	800	347	43.4	8.5
North Carolina	400	186	46.5	4.5
Oregon	400	180	45.0	4.4
Pennsylvania (excluding Philadelphia)	200	81	40.5	2.0
Philadelphia, PA	400	147	36.8	3.6
Puerto Rico	400	177	44.3	4.3
San Francisco, CA	400	165	41.3	4.0
Texas (excluding Houston)	400	157	39.3	3.8
Virginia	400	152	38.0	3.7
Washington	400	185	46.3	4.5
Total	9,700	4,100	42.3	100

Note. Percentages might not sum to 100 because of rounding.
^a Not adjusted for eligibility.

Table 2. Selected characteristics of persons with diagnosed HIV infection—Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
Gender
Male	2,965	74.7	71.9–77.6
Female	1,042	23.2	20.3–26.1
Transgender^d	87	2.1	1.5–2.7
Sexual orientation
Lesbian or gay	1,675	41.9	37.7–46.0
Heterosexual or straight	1,912	45.9	41.6–50.2
Bisexual	359	9.2	7.7–10.7
Other	120	3.0	2.1–3.9
Race/ethnicity
American Indian/Alaska Native	—	—	—
Asian	38	1.0	0.6–1.4
Black/African American	1,708	41.5	32.5–50.5
Hispanic/Latino^e	933	22.4	14.5–30.4
Native Hawaiian/other Pacific Islander	—	—	—
White	1,195	29.2	24.3–34.1
Multiple races	191	4.6	3.4–5.8
Age at time of interview (years)
18–24	85	1.9	1.5–2.4
25–29	258	6.4	5.2–7.5
30–34	323	8.9	7.7–10.0
35–39	323	8.8	7.6–10.1
40–44	342	9.1	8.1–10.1
45–49	455	11.3	10.2–12.3
50–54	658	15.4	14.1–16.6
55–59	714	16.4	15.1–17.7
60–64	490	12.2	10.8–13.7
≥ 65	452	9.7	8.8–10.6
Education
Less than high school	688	16.3	15.0–17.6
High school diploma or GED	1,103	26.7	25.0–28.5
More than high school	2,296	57.0	54.7–59.2
Country or territory of birth
United States or U.S. territory	3,479	84.9	82.9–87.0
Foreign born	609	15.1	13.0–17.1
Time since HIV diagnosis (years)
< 5	556	13.8	12.1–15.4
5–9	726	18.7	16.9–20.5
≥10	2,814	67.5	65.8–69.2
Homeless at any time, past 12 months^f
Yes	372	9.3	8.1–10.5
No	3,717	90.7	89.5–91.9
Moved in with other people because of financial problems, past 12 months
Yes	511	13.0	11.7–14.3
No	3,578	87.0	85.7–88.3
Number of times moved, past 12 months
0	3,004	72.7	70.6–74.7
1	679	17.5	16.1–18.8
≥ 2	400	9.9	8.6–11.1
Evicted from housing, past 12 months
Yes	106	2.8	1.9–3.6
No	3,983	97.2	96.4–98.1
Incarcerated >24 hours, past 12 months
Yes	148	3.9	3.0–4.8
No	3,938	96.1	95.2–97.0
Health insurance or coverage for care or medications, past 12 months^g
Yes	4,024	97.9	97.1–98.6
No	47	2.1	1.4–2.9
Type of health insurance or coverage for care or medications, past 12 months
Ryan White HIV/AIDS Program
Yes	1,950	46.1	43.4–48.8
No	2,030	53.9	51.2–56.6
Medicaid
Yes	1,886	45.3	43.1–47.5
No	2,149	54.7	52.5–56.9
Medicare
Yes	1,176	27.8	26.1–29.6
No	2,813	72.2	70.4–73.9
Private health insurance
Yes	1,388	34.0	31.2–36.7
No	2,599	66.0	63.3–68.8
Other public insurance
Yes	—	—	—
No	—	—	—
Tricare/CHAMPUS or Veterans Administration
Yes	122	4.2	3.3–5.1
No	3,844	95.8	94.9–96.7
Insurance type unknown^h
Yes	35	0.7	0.3–1.1
No	3,940	99.3	98.9–99.7
Any disabilityⁱ
Yes	1,797	42.6	40.7–44.4
No	2,288	57.4	55.6–59.3
Received Supplemental Security Income (SSI), past 12 months
Yes	776	17.8	15.7–19.8
No	3,278	82.2	80.2–84.3
Received Social Security Disability Insurance (SSDI), past 12 months
Yes	843	20.7	18.4–23.0
No	3,197	79.3	77.0–81.6
Perception of general health
Poor	226	5.3	4.1–6.6
Fair	1,007	24.0	22.6–25.4
Good	1,428	35.6	34.0–37.2
Very good	865	21.4	19.7–23.1
Excellent	555	13.6	12.2–15.1
Went without food due to lack of money, past 12 months
Yes	781	19.9	18.0–21.8
No	3,302	80.1	78.2–82.0
Employment status^j
Employed	1,941	48.6	46.9–50.3
Unemployed	1,710	41.1	38.9–43.3
Student	42	1.3	0.8–1.7
Retired	385	9.1	7.7–10.4
Combined yearly household income (U.S.$)^k
0–19,999	1,956	51.1	48.3–53.8
20,000–39,999	820	23.1	21.5–24.8
40,000–74,999	534	14.8	13.3–16.2
≥75,000	430	11.0	9.4–12.6
Poverty guidelines^l
Above poverty threshold	2,145	58.4	55.1–61.6
At or below poverty threshold	1,593	41.6	38.4–44.9
Total	4,100	100

Abbreviations: CI, confidence interval; GED, general educational development; CHAMPUS, Civilian Health and Medical Program of the Uniformed Services; U.S.$, U.S. dollar; HHS, Department of Health and Human Services [footnotes only].
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥ 0.30, estimates based on a denominator sample size < 30, “don’t know” responses, and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.
^e Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category.
^f Living on the street, in a shelter, in a single-room–occupancy hotel, or in a car.
^g Persons could select more than 1 response for health insurance or coverage for care or medications.
^h Unknown insurance type means that the person had insurance or coverage for care or medications, but the type of insurance or coverage could not be determined.
ⁱ Includes physical, mental, and emotional disabilities.
^j Employed includes employed for wages, self-employed, or homemaker.
^k Income from all sources, before taxes, in the last calendar year.
^l Poverty guidelines as defined by HHS; the 2018 guidelines were used for persons interviewed in 2019 and the 2019 guidelines were used for persons interviewed in 2020. More information regarding HHS poverty guidelines can be found at https://aspe.hhs.gov/frequently-asked-questions-related-poverty-guidelines-and-poverty.external icon

Table 3. Stage of disease, CD4 counts, and viral suppression during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
HIV infection stage 3 (AIDS)^d
Yes	2,440	57.3	55.4–59.1
No	1,659	42.7	40.9–44.6
Geometric mean CD4 count (cells/µL)
0–199	267	8.3	7.3–9.2
200–349	361	10.6	9.2–12.0
350–499	549	17.7	16.3–19.0
≥500	2,095	63.5	61.5–65.4
Lowest CD4 count (cells/µL), past 12 months
0–49	93	2.9	2.3–3.6
50–199	252	7.6	6.8–8.5
200–349	442	13.3	11.8–14.8
350–499	609	19.1	17.7–20.5
≥500	1,876	57.1	55.2–58.9
Viral suppression
Most recent viral load documented undetectable or <200 copies/mL	2,984	66.9	61.8–72.0
Most recent viral load documented detectable, ≥200 copies/mL, or missing/unknown	1,116	33.1	28.0–38.2
Sustained viral suppression
All viral load measurements documented undetectable or <200 copies/mL	2,707	61.0	56.4–65.5
Any viral load ≥200 copies/mL or missing/unknown	1,393	39.0	34.5–43.6
Total	4,100	100

Abbreviations: CD4, CD4 T-lymphocyte count (cells/µL); CI, confidence interval; CDC, Centers for Disease Control and Prevention [footnotes only].
Source of disease stage information: CDC. Revised surveillance case definition for HIV infection—United States, 2014. MMWR 2014;63(RR-03):1–10. https://www.cdc.gov/mmwr/indrr_2014.html. Accessed June 23, 2021.
Note. CD4 counts and viral load measurements are from medical record abstraction.
Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d HIV infection, stage 3 (AIDS): documentation of an AIDS-defining condition or either a CD4 count of <200 cells/µL or a CD4 percentage of total lymphocytes of <14. Documentation of an AIDS-defining condition supersedes a CD4 count or percentage that would not, by itself, be the basis for a stage 3 (AIDS) classification.

Table 4. Receipt of HIV care, ART prescription, PCP prophylaxis, and influenza vaccination among persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
Ever received outpatient HIV care^d
Yes	—	—	—
No	—	—	—
Received outpatient HIV care, past 12 months^d
Yes	4,032	96.5	95.1–97.8
No	64	3.5	2.2–4.9
Received outpatient HIV care, past 24 months^d
Yes	—	—	—
No	—	—	—
Retained in care, past 12 months^e
Yes	3,253	79.2	76.5–81.9
No	589	20.8	18.1–23.5
Retained in care, past 24 months^e
Yes	2,535	61.1	57.7–64.5
No	1,304	38.9	35.5–42.3
Prescribed ART, past 12 months^f
Yes	3,542	82.6	80.9–84.3
No	558	17.4	15.7–19.1
Prescribed PCP prophylaxis, past 12 months^g
Yes	99	33.4	23.2–43.5
No	193	66.6	56.5–76.8
Received influenza vaccination, past 12 months
Yes	3,140	75.8	73.7–77.9
No	915	24.2	22.1–26.3
Total	4,100	100

Abbreviations: CI, confidence interval; ART, antiretroviral therapy; PCP, Pneumocystis pneumonia; CD4, CD4 T-lymphocyte count (cells/µL) [footnotes only].
Note. CD4 counts, viral load measurements, and prophylaxes are from medical record abstraction. Influenza vaccination was obtained through interview. Measurement period is the 12 months before interview unless otherwise noted.
Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥ 0.30, estimates based on a denominator sample size < 30, “don’t know” responses, and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Outpatient HIV care was defined as any documentation of the following: encounter with an HIV care provider, viral load test result, CD4 test result, HIV resistance test or tropism assay, ART prescription, PCP prophylaxis, or MAC prophylaxis.
^e Two elements of outpatient HIV care at least 90 days apart in each 12-month period.
^f ART prescription documented in medical record; persons with no medical record abstraction were considered to have no documentation of ART prescription.
^g Among persons with CD4 cell count < 200 cells/µL.

Table 5. Sexually transmitted disease testing during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	Total population			Sexually active^a persons only
	No.^b	%^c	5% CI^d	No.^b	%^c	5% CI^d
Gonorrhea^e
Yes, received test	1,749	45.1	40.5–49.7	1,115	50.4	45.7–55.1
No test documented	1,994	54.9	50.3–59.5	1,002	49.6	44.9–54.3
Chlamydia^f
Yes, received test	1,749	45.1	40.3–49.8	1,119	50.5	45.6–55.4
No test documented	1,994	54.9	50.2–59.7	998	49.5	44.6–54.4
Syphilis^g
Yes, received test	2,408	61.6	58.0–65.1	1,458	65.3	61.8–68.8
No test documented	1,335	38.4	34.9–42.0	659	34.7	31.2–38.2
Gonorrhea, chlamydia, and syphilis
Yes, received all 3 tests	1,560	40.2	36.0–44.4	1,005	45.3	40.8–49.7
Fewer than 3 tests documented	2,183	59.8	55.6–64.0	1,112	54.7	50.3–59.2
Total	4,100	100		2,307	100

Abbreviations: CI, confidence interval; DFA, direct fluorescent antibody [footnotes only]; EIA, enzyme immunoassay [footnotes only]; ELISA, enzyme- linked immunoassay [footnotes only]; FTA-ABS, fluorescent treponemal antibody absorbed [footnotes only]; MHA-TP, microhemagglutination assay for antibody to Treponema pallidum [footnotes only]; NAAT, nucleic acid amplification test [footnotes only]; RPR, rapid plasma reagin [footnotes only]; TP- PA, T. pallidum particle agglutination [footnotes only]; TPHA, T. pallidum hemagglutination assay [footnotes only]; VDRL, Venereal Disease Research Laboratory [footnotes only].
Note. Information on laboratory testing for sexually transmitted diseases was based on medical record abstraction. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Sexual activity was reported in the interview component of the Medical Monitoring Project and was defined as anal or vaginal intercourse.
^b Numbers are unweighted.
^c Percentages are weighted percentages.
^d CIs incorporate weighted percentages.
^e Testing for Neisseria gonorrhoeae was defined as documentation of a result from culture, gram stain, EIA, NAAT, or nucleic acid probe performed on a specimen from any anatomical site for screening or diagnostic purposes.
^f Chlamydia trachomatis testing was defined as a result from culture, DFA, EIA or ELISA, NAAT, or nucleic acid probe performed on a specimen from any anatomical site for screening or diagnostic purposes.
^g Syphilis testing was defined as a result from nontreponemal syphilis tests (RPR or VDRL), treponemal syphilis tests (TPHA, TP-PA, MHA-TP, or FTA- ABS tests), or dark-field microscopy performed for screening or diagnostic purposes.

Table 6. Emergency department visits and hospital admissions during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project,
United States, 2019
	No.^a	%^b	95% CI^c
Number of visits to emergency department
0	2,360	58.1	55.5–60.7
1	763	18.2	17.1–19.3
2–4	772	19.3	17.4–21.3
≥5	183	4.4	3.6–5.2
Number of hospital admissions
0	3,271	80.9	79.5–82.2
1	456	11.0	10.0–12.0
2–4	298	7.1	6.2–7.9
≥5	49	1.1	0.7–1.5
Total	4,100	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.

Table 7. Antiretroviral therapy (ART) use and reasons for not taking ART among persons with diagnosed HIV— Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
Ever taken ART
Yes	4,026	98.2	97.5–98.9
No	48	1.8	1.1–2.5
Currently taking ART
Yes	3,930	94.4	93.1–95.8
No	144	5.6	4.2–6.9
Reasons for never taking ART^d
Health care provider never discussed taking ART with person
Yes	—	—	—
No	—	—	—
Health care provider said person should not start taking ART
Yes	—	—	—
No	—	—	—
Money or insurance problems
Yes	—	—	—
No	—	—	—
Person did not believe they needed ART
Yes	19	57.5*	36.4–78.5
No	13	42.5*	21.5–63.6
Person thinks ART would make them feel sick or harm them
Yes	—	—	—
No	—	—	—
Person decided not to take ART for some other reason
Yes	12	34.5*	14.3–54.7
No	20	65.5*	45.3–85.7
Reasons for not currently taking ART, among those persons with a history of ART use^d
Health care provider never discussed restarting ART with person
Yes	23	29.4	17.8–41.1
No	73	70.6	58.9–82.2
Health care provider said person should not take ART
Yes	—	—	—
No	—	—	—
Money or insurance problems
Yes	42	50.5	39.4–61.6
No	54	49.5	38.4–60.6
Person did not believe they needed ART
Yes	—	—	—
No	—	—	—
Person thinks ART would make them feel sick or harm them
Yes	23	30.1*	15.0–45.1
No	73	69.9*	54.9–85.0
Person decided not to take ART for some other reason
Yes	43	43.7	29.5–57.9
No	53	56.3	42.1–70.5
Total	4,100	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥0.30, estimates based on a denominator sample size <30, “don’t know” responses, and skipped (missing) responses. Estimates with an absolute CI width ≥ 0.30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (*) and should be interpreted with caution.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Persons could select more than 1 response for reasons not taking ART.

Table 8. Antiretroviral therapy (ART) adherence and reasons for missing ART doses among persons with diagnosed HIV taking ART—Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
ART adherence in the past 30 days
How many days did you miss at least 1 dose of any of your HIV medicines?
0	2,385	61.1	58.5–63.8
1–2	992	25.0	23.3–26.8
3–5	340	8.6	7.4–9.8
6–10	120	3.2	2.6–3.9
11+	74	2.0	1.5–2.5
How well did you do at taking your HIV medicines in the way you were supposed to?
Very poor	38	0.9	0.6–1.2
Poor	52	1.3	0.9–1.8
Fair	194	5.3	4.5–6.0
Good	444	11.4	10.1–12.7
Very good	1,043	26.4	24.2–28.6
Excellent	2,157	54.7	52.5–56.9
How often did you take your HIV medicines in the way you were supposed to?
Never	24	0.6	0.3–0.8
Rarely	34	0.9	0.5–1.2
Sometimes	91	2.5	2.0–3.1
Usually	179	4.7	4.1–5.4
Almost always	876	22.6	20.8–24.4
Always	2,722	68.7	66.6–70.9
How often were you troubled by ART side effects?
Never	2,961	75.9	72.8–79.0
Rarely	514	13.6	11.8–15.5
About half the time	183	4.9	3.9–6.0
Most of the time	114	2.7	2.1–3.3
Always	124	2.9	2.3–3.5
Reasons for last missed ART dose among persons who ever missed a dose^d
Had a problem paying for HIV medicines
Yes	146	5.1	4.1–6.1
No	2,762	94.9	93.9–95.9
Had a problem getting a prescription or a refill for HIV medicines
Yes	530	19.5	16.1–22.9
No	2,378	80.5	77.1–83.9
In the hospital or too sick to take HIV medicines
Yes	252	8.3	7.4–9.1
No	2,656	91.7	90.9–92.6
Fell asleep early or overslept
Yes	1,038	35.2	33.2–37.3
No	1,868	64.8	62.7–66.8
Change in your daily routine or were out of town
Yes	1,190	40.2	37.7–42.8
No	1,717	59.8	57.2–62.3
Had side effects from your HIV medicines
Yes	300	9.9	8.7–11.2
No	2,602	90.1	88.8–91.3
Felt depressed or overwhelmed
Yes	509	17.1	15.7–18.5
No	2,397	82.9	81.5–84.3
Was drinking or using drugs
Yes	310	9.7	8.6–10.8
No	2,597	90.3	89.2–91.4
Forgot to take HIV medicines
Yes	1,768	60.0	57.5–62.5
No	1,137	40.0	37.5–42.5
Did not feel like taking HIV medicines
Yes	366	11.9	10.4–13.4
No	2,538	88.1	86.6–89.6
Total	3,930	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Persons could report more than 1 reason for missed last dose.

Table 9. Antiretroviral therapy (ART) prescription, ART dose adherence, sustained viral suppression, and geometric mean CD4 count among persons with diagnosed HIV, by selected characteristics—Medical Monitoring Project, United States, 2019
	Prescription of ART^a			ART dose adherence^b			Sustained viral suppression^c			Geometric mean CD4 count ≥ 200^d
	No.^e	Row %^f	95% CI^g	No.^e	Row %^f	95% CI^g	No.^e	Row %^f	95% CI^g	No.^e	Row %^f	95% CI^g
Gender
Male	2,567	82.6	80.6–84.6	1,728	61.1	58.3–63.8	1,994	62.0	56.6–67.4	2,204	92.3	91.1–93.4
Female	903	83.2	80.3–86.1	615	61.9	57.8–66.0	661	59.2	55.8–62.5	744	90.2	88.0–92.3
Transgender^h	68	76.0	64.5–87.5	39	52.6	41.3–63.8	50	49.8	39.5–60.2	55	93.1	86.8–99.4
Sexual orientation
Lesbian or gay	1,466	83.6	80.9–86.3	963	60.0	56.5–63.5	1,170	63.7	56.8–70.5	1,274	94.5	93.2–95.8
Heterosexual or straight	1,635	81.5	79.5–83.5	1,163	63.9	61.2–66.6	1,216	58.8	55.2–62.4	1,358	88.9	87.3–90.5
Bisexual	307	81.7	76.4–86.9	189	57.9	48.2–67.7	226	59.3	52.1–66.5	259	93.6	91.0–96.1
Other	105	86.6	77.6–95.6	53	42.7	32.6–52.8	71	57.8	49.3–66.3	88	90.5	84.1–96.8
Race/ethnicity
American Indian/Alaska Native	—	—	—	—	—	—	—	—	—	—	—	—
Asian	33	84.6	71.4–97.7	25	69.8*	54.5–85.1	29	69.7*	50.6–88.9	30	100*
Black/African American	1,444	80.2	77.5–82.9	964	60.5	56.6–64.5	1,043	55.9	51.4–60.4	1,213	90.0	88.4–91.6
Hispanic/Latinoⁱ	827	86.2	83.2–89.2	524	57.2	52.7–61.7	654	66.8	61.4–72.3	716	91.3	89.1–93.5
Native Hawaiian/other Pacific Islander	—	—	—	—	—	—	—	—	—	—	—	—
White	1,050	84.5	81.7–87.3	765	66.8	61.7–71.8	854	65.6	58.4–72.9	891	95.1	93.8–96.4
Multiple races	159	77.9	69.5–86.3	93	50.4	40.5–60.3	108	51.0	39.9–62.1	134	87.6	81.8–93.5
Age at time of interview (years)
18–29	278	76.4	70.0–82.8	132	44.2	36.2–52.2	186	49.3	41.4–57.2	250	92.2	88.6–95.8
30–39	560	79.9	76.1–83.6	314	51.3	45.2–57.3	380	52.8	46.8–58.9	473	91.6	88.9–94.3
40–49	683	81.9	78.8–84.9	466	61.8	56.6–66.9	487	56.2	50.6–61.7	557	89.2	87.1–91.2
≥50	2,021	84.7	82.7–86.8	1,473	66.4	63.7–69.2	1,654	67.2	62.3–72.2	1,725	92.7	91.2–94.1
Total	3,542	82.6	80.9–84.3	2,385	61.1	58.5–63.8	2,707	61.0	56.4–65.5	3,005	91.7	90.8–92.7

Abbreviations: CD4, CD4 T-lymphocyte count (cells/µL); CI, confidence interval.
Note. Numbers might not add to total because of missing data.
Excluded are estimates with a coefficient of variation ≥ 0.30, estimates based on a denominator sample size <30, “don’t know” responses, and skipped (missing) responses. Estimates with an absolute CI width ≥ 0.30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (*) and should be interpreted with caution.
^a Prescription of ART was based on documentation in the medical record in the 12 months before interview.
^b In past 30 days, 100% adherence to ART doses.
^c All viral load measurements in the 12 months before interview documented undetectable or <200 copies/mL.
^d Geometric mean CD4 count was abstracted from medical records and based on the 12 months before interview.
^e Numbers are unweighted.
^f Percentages are weighted percentages.
^g CIs incorporate weighted percentages.
^h Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.
ⁱ Hispanics or Latinos might be of any race. Persons are classified in only 1 race/ethnicity category.

Table 10. Depression and anxiety during the 2 weeks before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
Depression based on DSM-IV criteria^d
No depression	3,377	83.9	82.0–85.8
Other depression	296	7.3	6.3–8.3
Major depression	361	8.8	7.4–10.1
Moderate or severe depression (PHQ-8 score ≥ 10)
Yes	547	13.3	11.4–15.2
No	3,491	86.7	84.8–88.6
Anxiety^e
No anxiety	3,201	78.7	75.9–81.4
Mild anxiety	222	5.4	4.6–6.1
Moderate anxiety	331	8.7	7.1–10.3
Severe anxiety	296	7.2	5.7–8.8
Total	4,100	100

Abbreviations: CI, confidence interval; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GAD-7, Generalized Anxiety Disorder 7-item Scale [footnotes only]; PHQ-8, Patient Health Questionnaire.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Responses to the items on the PHQ-8 were used to define “major depression” and “other depression” according to criteria from the DSM-IV. “Major depression” was defined as having at least 5 symptoms of depression; “other depression” was defined as having 2–4 symptoms of depression.
^e Responses to the GAD-7 were used to define “mild anxiety,” “moderate anxiety,” and “severe anxiety” according to criteria from the DSM-IV. “Severe anxiety” was defined as having a score of ≥ 15; “moderate anxiety” was defined as having a score of 10–14; and “mild anxiety” was defined as having a score of 5–9.

Table 11. Tobacco and electronic cigarette use among persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
Smoked ≥ 100 cigarettes (lifetime)
Yes	2,152	52.6	49.3–56.0
No	1,910	47.4	44.0–50.7
Cigarette smoking status
Never smoked	1,910	47.4	44.0–50.7
Former smoker	889	21.2	19.0–23.3
Current smoker	1,261	31.5	29.0–33.9
Frequency of current cigarette smoking
Never	2,799	68.5	66.1–71.0
Daily	1,029	25.9	23.8–28.0
Weekly	122	2.8	2.3–3.3
Monthly	38	1.0	0.6–1.5
Less than monthly	72	1.7	1.3–2.1
Smoked ≥ 50 cigars, cigarillos, or little filtered cigars (lifetime)
Yes	553	14.3	12.6–16.0
No	3,515	85.7	84.0–87.4
Cigars, cigarillos, or little filtered cigars smoking status
Never smoked	3,515	85.7	84.0–87.4
Former smoker	275	6.9	6.0–7.7
Current smoker	278	7.5	6.0–8.9
Frequency of current cigars, cigarillos, or little filtered cigars smoking
Never	3,790	92.5	91.1–94.0
Daily	77	2.1	1.4–2.9
Some days	72	1.9	1.4–2.5
Rarely	129	3.4	2.7–4.1
Electronic cigarette smoking status
Never used electronic cigarettes	3,042	73.5	69.7–77.3
Used electronic cigarettes, but not in the past 30 days	817	21.0	17.7–24.3
Used electronic cigarettes in the past 30 days	210	5.5	4.6–6.5
Total	4,100	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.

Table 12. Alcohol use during the 12 months before interview among persons with diagnosed HIV— Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
Any alcohol use^d
Yes	2,481	61.0	58.2–63.9
No	1,588	39.0	36.1–41.8
Frequency of alcohol use
Daily	248	6.1	5.2–6.9
Weekly	747	18.1	16.5–19.6
Monthly	506	12.4	11.4–13.5
Less than monthly	980	24.5	23.1–25.8
Never	1,588	39.0	36.1–41.8
Binge drinking, past 30 days^e
Yes	601	14.8	12.7–16.9
No	3,449	85.2	83.1–87.3
Total	4,100	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Persons who drank at least 1 alcoholic beverage during the 12 months before interview. Alcoholic beverage was defined as a 12-ounce beer, 5-ounce glass of wine, or 1.5-ounce shot of liquor.
^e Persons who drank ≥ 5 alcoholic beverages in a single sitting (≥ 4 for women) during the 30 days before interview.

Table 13. Noninjection drug use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
Use of any noninjection drugs^d
Yes	1,310	31.9	29.3–34.4
No	2,744	68.1	65.6–70.7
Noninjection drugs used^d
Marijuana
Yes	1,170	28.5	26.0–30.9
No	2,884	71.5	69.1–74.0
Crack
Yes	121	3.1	2.3–3.9
No	3,933	96.9	96.1–97.7
Cocaine that is smoked or snorted
Yes	237	6.0	5.0–7.0
No	3,817	94.0	93.0–95.0
Methamphetamine (e.g., crystal meth, tina, crank, ice)
Yes	218	5.4	4.1–6.6
No	3,833	94.6	93.4–95.9
Amphetamine (e.g., speed, bennies, uppers)
Yes	66	1.5	1.0–1.9
No	3,985	98.5	98.1–99.0
Club drugs (e.g., Ecstasy or X, ketamine or Special K, GHB or Liquid Ecstasy)
Yes	159	3.7	2.8–4.5
No	3,895	96.3	95.5–97.2
Amyl nitrite (poppers)
Yes	293	6.9	5.5–8.4
No	3,761	93.1	91.6–94.5
Prescription opioids (e.g., oxycodone, hydrocodone, Vicodin, Percocet)^e
Yes	102	2.7	2.0–3.4
No	3,952	97.3	96.6–98.0
Prescription tranquilizers (e.g., Valium, Ativan, Xanax, downers, nerve pills)^e
Yes	75	1.8	1.3–2.3
No	3,978	98.2	97.7–98.7
Total	4,100	100

Disclaimer: The use of trade names is for identification only and does not imply endorsement by the Department of Health and Human Services or the Centers for Disease Control and Prevention.
Abbreviations: CI, confidence interval; GHB, gamma hydroxybutyrate.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
Persons could report taking more than 1 noninjection drug.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Includes all drugs that were not injected (i.e., administered by any route other than injection), including legal drugs that were not used for medical purposes.
^e Not prescribed, or prescribed but taken more than directed.

Table 14. Injection drug use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
Use of any injection drugs
Yes	109	2.7	1.9–3.4
No	3,949	97.3	96.6–98.1
Injection drugs used
Cocaine
Yes	—	—	—
No	—	—	—
Heroin
Yes	28	0.5	0.2–0.7
No	4,029	99.5	99.3–99.8
Heroin and cocaine (speedball)
Yes	—	—	—
No	—	—	—
Methamphetamine (e.g., crystal meth, tina, crank, ice)
Yes	84	2.3	1.5–3.0
No	3,972	97.7	97.0–98.5
Amphetamine (e.g., speed, bennies, uppers)
Yes	—	—	—
No	—	—	—
Prescription opioids (e.g., OxyContin, oxycodone, hydrocodone)
Yes	—	—	—
No	—	—	—
Total	4,100	100

Disclaimer: The use of trade names is for identification only and does not imply endorsement by the Department of Health and Human Services or the Centers for Disease Control and Prevention.
Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥ 0.30, estimates based on a denominator sample size < 30, “don’t know” responses, and skipped (missing) responses.
Persons could report taking more than 1 injection drug.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.

Table 15. Gynecological care and reproductive health among women with diagnosed HIV— Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
Papanicolaou (Pap) test, past 3 years^d
Yes	903	87.5	84.2–90.9
No	128	12.5	9.1–15.8
Pregnant since HIV diagnosis
Yes	283	28.4	23.0–33.8
No	747	71.6	66.2–77.0
Total	1,042	100

Abbreviation: CI, confidence interval.
Note. Measures are self-reported. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding.
Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Or since HIV diagnosis for women with a diagnosis within the past 3 years.

Table 16. Sexual behavior during the 12 months before interview among cisgender men and women with diagnosed HIV—Medical Monitoring Project, United States, 2019
	Men			Women
Behavior	No.^a	%^b	95% CI^c	No.^a	%^b	95% CI^c
Engaged in anal sex with men
Receptive
Yes	997	34.7	31.6–37.8	51	4.8	3.2–6.4
No	1,872	65.3	62.2–68.4	972	95.2	93.6–96.8
Insertive
Yes	923	32.3	30.2–34.4	NA	NA	NA
No	1,945	67.7	65.6–69.8	NA	NA	NA
Engaged in anal sex with women
Yes	59	2.0	1.5–2.4	NA	NA	NA
No	2,892	98.0	97.6–98.5	NA	NA	NA
Engaged in vaginal sex
Yes	516	18.2	15.5–20.9	512	50.0	45.6–54.4
No	2,378	81.8	79.1–84.5	514	50.0	45.6–54.4
Engaged in vaginal or anal sex
Yes	1,733	60.6	58.3–63.0	514	50.2	45.7–54.6
No	1,150	39.4	37.0–41.7	512	49.8	45.4–54.3
Number of vaginal or anal sex partners among
MSM^d
Mean	7			NA
Median	2			NA
Range	1–300			NA
MSW^e
Mean	2			NA
Median	1			NA
Range	1–90			NA
WSM^f
Mean	NA			1
Median	NA			1
Range	NA			1–70
Total	2,965	100		1,042	100

Abbreviations: CI, confidence interval; NA, not applicable; MSM, men who had sex with men; MSW, men who had sex only with women; WSM, women who had sex with men.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Among men who had anal sex with men in the 12 months before interview.
^e Among men who had vaginal or anal sex only with women in the 12 months before interview.
^f Among women who had vaginal or anal sex with men in the 12 months before interview.

Table 17. Sexual behavior during the 12 months before interview among transgender persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	Transgender^a,b			Transgender women^a			Transgender men^b
Behavior	No.^c	%^d	95% CI^e	No.^c	%^d	95% CI^e	No.^c	%^d	95% CI^e
Engaged in vaginal or anal sex
Yes	56	74.7	62.1–87.3	51	77.4	64.8–90.1	—	—	—
No	27	25.3	12.7–37.9	22	22.6	9.9–35.2	—	—	—
Engaged in vaginal or anal sex with men
Yes	52	70.4	58.2–82.6	50	77.0	64.2–89.7	—	—	—
No	31	29.6	17.4–41.8	23	23.0	10.3–35.8	—	—	—
Engaged in vaginal or anal sex with women
Yes	—	—	—	—	—	—	—	—	—
No	—	—	—	—	—	—	—	—	—
Engaged in vaginal or anal sex with transgender partners
Yes	—	—	—	—	—	—	—	—	—
No	—	—	—	—	—	—	—	—	—
Reported any high-risk sex^f
Yes	—	—	—	—	—	—	—	—	—
No	—	—	—	—	—	—	—	—	—
Number of vaginal or anal sex partners^g
Mean	5			5			7
Median	2			2			1
Range	1–100			1–100			1–30
Total	87	100		77	100		8	100

Abbreviations: CI, confidence interval; PrEP, preexposure prophylaxis [footnotes only].
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding.
Excluded are estimates with a coefficient of variation ≥ 0.30, estimates based on a denominator sample size <30, “don’t know” responses, and skipped (missing) responses.
^a Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender. When reported sex at birth and gender were different, persons who reported that their sex assigned at birth was male, but identified as female or transgender, were classified as transgender women.
^b Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender. When reported sex at birth and gender were different, persons who reported that their sex assigned at birth was female, but identified as male or transgender, were classified as transgender men.
^c Numbers are unweighted.
^d Percentages are weighted percentages.
^e CIs incorporate weighted percentages.
^f Vaginal or anal sex with at least 1 partner with an HIV-negative or unknown status while not having sustained viral suppression (defined as HIV viral load <200 copies/mL documented in the medical record at every measure in the 12 months before interview), a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the 5 most recent partners.
^g Among persons who had vaginal or anal sex in the 12 months before interview.

Table 18. Sexual behavior during the 12 months before interview among men who had sex with men (MSM), men who had sex only with women (MSW), and women who had sex with men (WSM) with diagnosed HIV—Medical Monitoring Project, United States, 2019
	MSM			MSW			WSM
Behavior	No.^a	%^b	95% CI^c	No.^a	%^b	95% CI^c	No.^a	%^b	95% CI^c
Engaged in any high-risk sex^d
Yes	153	8.8	6.8–10.7	32	4.6	3.1–6.1	69	7.1	5.2–8.9
No	1,841	91.2	89.3–93.2	834	95.4	93.9–96.9	930	92.9	91.1–94.8
Engaged in any high-risk sex (among sexually active persons)^d
Yes	153	13.6	10.7–16.5	32	8.8	5.8–11.9	69	14.0	11.0–17.0
No	1,120	86.4	83.5–89.3	411	91.2	88.1–94.2	437	86.0	83.0–89.0
Percentages of sexually active persons who used a prevention strategy with at least 1 partner
Sex while having sustained viral suppression^e
Yes	865	62.7	57.3–68.1	290	60.0	54.3–65.6	316	56.2	50.9–61.4
No	416	37.3	31.9–42.7	158	40.0	34.4–45.7	198	43.8	38.6–49.1
Condom-protected sex^f
Yes	684	55.8	52.9–58.6	297	68.9	64.8–73.0	261	53.9	49.6–58.1
No	572	44.2	41.4–47.1	137	31.1	27.0–35.2	238	46.1	41.9–50.4
Condomless sex with a partner on PrEP^g
Yes	237	16.8	14.4–19.1	20	4.0	1.8–6.1	12	2.3	1.0–3.6
No	1,033	83.2	80.9–85.6	427	96.0	93.9–98.2	502	97.7	96.4–99.0
Sex with a partner with HIV^h
Yes	745	57.3	53.8–60.7	105	20.4	16.6–24.2	122	22.6	18.5–26.7
No	536	42.7	39.3–46.2	343	79.6	75.8–83.4	392	77.4	73.3–81.5
Total	2,023	100		880	100		1,015	100

Abbreviations: CI, confidence interval; PrEP, preexposure prophylaxis.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Persons who reported no anal, vaginal, or oral sex in the 12 months before interview were categorized according to self-reported sexual orientation. This table does not include information on women who had sex with women only, women who had sex with transgender persons only, or men who had sex with transgender persons only.
Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Vaginal or anal sex with at least 1 partner with an HIV-negative or unknown status while not having sustained viral suppression (defined as HIV viral load <200 copies m/L documented in the medical record at every measure in the 12 months before interview), a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the 5 most recent partners.
^e HIV viral load <200 copies/mL documented in the medical record at every measure in the 12 months before interview.
^f Condoms were consistently used with at least 1 vaginal or anal sex partner.
^g At least 1 condomless-sex partner without HIV was on PrEP. PrEP use was only measured among the 5 most recent partners and was reported by the partner with HIV.
^h Sex with at least 1 partner with HIV.

Table 19. Met and unmet needs for ancillary services during the 12 months before interview among persons with diagnosed HIV— Medical Monitoring Project, United States, 2019
	Persons who received services			Persons who needed but did not receive services by time of interview
	No.^a	%^b	95% CI^c	No.^a	%^b	95% CI^c
*HIV support services*
HIV case management services
Yes	2,393	56.7	52.8–60.7	241	7.0	5.8–8.3
No	1,658	43.3	39.3–47.2	3,810	93.0	91.7–94.2
Medicine through ADAP
Yes	1,950	46.5	43.9–49.1	98	3.0	2.4–3.6
No	2,009	53.5	50.9–56.1	3,861	97.0	96.4–97.6
Professional help remembering to take HIV medicines on time or correctly (adherence support services)
Yes	1,453	35.1	32.6–37.7	25	0.7	0.4–0.9
No	2,593	64.9	62.3–67.4	4,021	99.3	99.1–99.6
Patient navigation services
Yes	668	15.2	13.0–17.5	157	4.2	3.3–5.2
No	3,386	84.8	82.5–87.0	3,897	95.8	94.8–96.7
HIV peer group support
Yes	528	12.4	10.9–13.8	259	6.7	5.4–8.0
No	3,525	87.6	86.2–89.1	3,794	93.3	92.0–94.6
*Non-HIV medical services*
Dental care
Yes	2,541	60.6	57.8–63.3	836	21.8	19.9–23.7
No	1,519	39.4	36.7–42.2	3,224	78.2	76.3–80.1
Mental health services
Yes	1,352	32.0	28.0–36.0	336	8.4	7.2–9.6
No	2,708	68.0	64.0–72.0	3,724	91.6	90.4–92.8
Drug or alcohol counseling or treatment
Yes	305	7.0	5.7–8.2	71	1.7	1.1–2.4
No	3,760	93.0	91.8–94.3	3,994	98.3	97.6–98.9
Domestic violence services
Yes	50	1.2	0.8–1.7	33	0.9	0.5–1.2
No	4,017	98.8	98.3–99.2	4,034	99.1	98.8–99.5
*Subsistence services*
SNAP or WIC
Yes	1,576	37.3	34.6–40.0	416	10.9	8.9–12.9
No	2,489	62.7	60.0–65.4	3,649	89.1	87.1–91.1
Transportation assistance
Yes	1,061	24.9	23.4–26.4	274	7.3	6.2–8.3
No	3,004	75.1	73.6–76.6	3,791	92.7	91.7–93.8
Meal or food services^d
Yes	879	21.0	18.3–23.8	303	7.6	6.5–8.6
No	3,186	79.0	76.2–81.7	3,762	92.4	91.4–93.5
Shelter or housing services
Yes	739	17.0	15.3–18.7	348	8.8	7.0–10.6
No	3,322	83.0	81.3–84.7	3,713	91.2	89.4–93.0
Total	4,100	100		4,100	100

Abbreviations: CI, confidence interval; ADAP, AIDS Drug Assistance Program; SNAP, Supplemental Nutrition Assistance Program; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children.
Note. Persons could report receiving or needing more than 1 service. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.
^d Includes services such as soup kitchens, food pantries, food banks, church dinners, or food delivery services.

Table 20. Physical violence by an intimate partner and forced sex among persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
Was ever slapped, punched, shoved, kicked, choked, or otherwise physically hurt by a romantic or sexual partner
Yes	1,043	25.2	23.0–27.3
No	2,993	74.8	72.7–77.0
Was slapped, punched, shoved, kicked, choked, or otherwise physically hurt by a romantic or sexual partner, past 12 months
Yes	175	4.4	3.7–5.1
No	3,856	95.6	94.9–96.3
Was ever threatened with harm or physically forced to have unwanted vaginal, anal, or oral sex
Yes	709	16.8	15.3–18.4
No	3,322	83.2	81.6–84.7
Was threatened with harm or physically forced to have unwanted vaginal, anal, or oral sex, past 12 months
Yes	58	1.3	1.0–1.6
No	3,968	98.7	98.4–99.0
Total	4,100	100

Abbreviation: CI, confidence interval.
Note. Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.

Table 21. Prevention services received during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	No.^a	%^b	95% CI^c
One-on-one HIV/STD risk-reduction conversation with physician, nurse, or other health care worker
Yes	2,465	60.7	57.2–64.1
No	1,606	39.3	35.9–42.8
One-on-one HIV/STD risk-reduction conversation with outreach worker, counselor, or prevention program worker
Yes	1,323	31.8	27.3–36.3
No	2,748	68.2	63.7–72.7
Attended an organized HIV/STD risk-reduction session involving a small group of people
Yes	517	12.1	9.9–14.2
No	3,555	87.9	85.8–90.1
Received free condoms
Yes	1,906	46.3	42.4–50.2
No	2,164	53.7	49.8–57.6
Total	4,100	100

Abbreviation: CI, confidence interval.
Note. Persons could report receiving more than 1 prevention service.
Numbers might not add to total because of missing data. Percentages might not sum to 100 because of rounding. Excluded are estimates with “don’t know” responses and skipped (missing) responses.
^a Numbers are unweighted.
^b Percentages are weighted percentages.
^c CIs incorporate weighted percentages.

Table 22. National indicators: homelessness, HIV stigma, and high-risk sex among persons with diagnosed HIV—Medical Monitoring Project, United States, 2019
	Homeless in the 12 months before interview among persons receiving HIV care in the past 12 months^a			HIV stigma^b			HIV stigma, past 12 months^c			Engaged in any sex without using an HIV prevention strategy in the 12 months before interview^d
	No.^e	%^f	95% CI^g	No.^e	Row median score	95% CI	No.^e	Row median score	95% CI	No.^e	%^f	95% CI^g
Gender
Male	250	8.5	7.2–9.8	2,831	36.2	33.8–38.6	2,824	28.9	27.5–30.3	186	7.3	5.9–8.8
Female	85	8.2	6.0–10.5	978	44.7	42.0–47.4	990	37.3	35.0–39.6	69	6.9	5.1–8.7
Transgender^h	21	27.3	15.0–39.7	85	40.5	29.8–51.3	84	32.3	24.4–40.1	–	–	–
Sexual orientation
Lesbian or gay	105	6.7	5.0–8.3	1,623	36.0	32.6–39.4	1,611	27.8	25.4–30.3	121	8.6	6.5–10.7
Heterosexual or straight	169	8.5	7.1–9.8	1,794	39.7	38.3–41.1	1,811	33.3	31.3–35.4	103	6.0	4.4–7.5
Bisexual	57	17.7	12.2–23.1	345	41.1	33.4–48.7	344	32.1	29.2–34.9	30	7.2	4.6–9.7
Other	23	18.8	10.2–27.5	115	36.8	31.1–42.5	115	31.0	26.0–36.0	12	12.5	5.8–19.2
Race/ethnicity
American Indian/Alaska Native	—	—	—	—	—	—	—	—	—	—	—	—
Asian	—	—	—	38	40.4	27.9–53.0	38	32.4	21.8–43.1	0	0*
Black/African American	171	10.6	7.8–13.3	1,630	37.8	35.6–40.1	1,633	30.8	29.5–32.2	105	6.5	4.9–8.0
Hispanic/Latinoⁱ	68	6.8	4.5–9.0	872	39.0	36.4–41.5	875	32.7	30.2–35.2	63	6.5	4.6–8.4
Native Hawaiian/other Pacific Islander	—	—	—	—	—	—	—	—	—	—	—	—
White	85	7.7	5.4–9.9	1,147	38.3	35.1–41.6	1,142	29.0	27.1–31.0	80	8.4	6.5–10.2
Multiple races	31	16.6	10.8–22.5	179	44.0	35.0–53.0	182	35.3	26.1–44.4	—	—	—
Age at time of interview (years)
18–29	54	16.5	11.3–21.7	333	42.9	39.2–46.6	329	38.2	35.5–40.9	49	14.9	10.0–19.9
30–39	79	11.9	9.2–14.7	616	41.3	37.8–44.8	615	33.9	31.0–36.8	71	12.7	9.5–15.8
40–49	72	9.7	7.2–12.1	765	40.6	37.7–43.4	765	32.4	30.4–34.4	51	7.4	5.3–9.4
≥50	153	6.6	5.3–8.0	2,186	35.8	34.1–37.5	2,195	28.4	27.4–29.4	96	4.5	3.4–5.7
Total	358	8.9	7.6–10.3	3,900	38.3	36.3–40.2	3,904	30.7	29.2–32.1	267	7.4	6.1–8.6

Abbreviations: CI, confidence interval; PrEP, preexposure prophylaxis [footnotes only].
Note. Numbers might not add to total because of missing data.
Excluded are estimates with a coefficient of variation ≥ 0.30, estimates based on a denominator sample size <30, “don’t know” responses, and skipped (missing) responses. Estimates with an absolute CI width≥ 30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (*) and should be interpreted with caution.
^a Living on the street, in a shelter, in a single-room–occupancy hotel, or in a car.
^b Ten-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures 4 dimensions of HIV stigma: personalized stigma since HIV diagnosis, current disclosure concerns, current negative self-image, and current perceived public attitudes about people living with HIV.
^c Ten-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures 4 dimensions of HIV stigma: personalized stigma during the past 12 months, current disclosure concerns, current negative self-image, and current perceived public attitudes about people living with HIV.
^d Vaginal or anal sex with at least 1 partner of HIV-negative or unknown status while not having sustained viral load suppression, a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the 5 most recent partners.
^e Numbers are unweighted.
^f Percentages are weighted percentages.
^g CIs incorporate weighted percentages.
^h Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender.
ⁱ Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category.

Behavioral and Clinical Characteristics of Persons Living with Diagnosed HIV Infection—Medical Monitoring Project, United States, 2019 Cycle: Tables